You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5332 Results
Guidelines and Advice
Status: Archived
ID: 20-3
Jan 2016
Guidelines and Advice
Status: In-Review
ID: RR SCT-9
Version: N/A
Jun 2020
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Guidelines and Advice
Status: Current
ID: PET 2024-1
Updated
Mar 2025
Guidelines and Advice
Status: In-Review
ID: GL-END 3-21
Jan 2018
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Guidelines and Advice
Status: In-Review
ID: GL END 3-24
Aug 2022
Guidelines and Advice
Status: Archived
ID: 15-15
Sep 2017
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015
Guidelines and Advice
Status: Current
ID: 17-4
Version: 2
Nov 2016
Document
New
Apr 2025
Document
New
Apr 2025

Pages